Last reviewed · How we verify
Rivaroxaban Oral Tablet [Xarelto] — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Rivaroxaban Oral Tablet [Xarelto] (Rivaroxaban Oral Tablet [Xarelto]) — Children's Hospital of Fudan University.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Rivaroxaban Oral Tablet [Xarelto] TARGET | Rivaroxaban Oral Tablet [Xarelto] | Children's Hospital of Fudan University | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Rivaroxaban Oral Tablet [Xarelto] CI watch — RSS
- Rivaroxaban Oral Tablet [Xarelto] CI watch — Atom
- Rivaroxaban Oral Tablet [Xarelto] CI watch — JSON
- Rivaroxaban Oral Tablet [Xarelto] alone — RSS
Cite this brief
Drug Landscape (2026). Rivaroxaban Oral Tablet [Xarelto] — Competitive Intelligence Brief. https://druglandscape.com/ci/rivaroxaban-oral-tablet-xarelto. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab